Jeffrey Kindler
Latest Jeffrey Kindler News
-
Earnings Preview: Pfizer to Report on 2nd Quarter
few years. That problem, and Pfizer's lagging stock price, led the board last December to oust Read's predecessor, Jeffrey Kindler , who had temporarily shored up the company with the Wyeth acquisition and intense cost-cutting ever since. Read has
-
Pfizer to Buy Pain Drug Developer Icagen for $56M
recent years. That's depressed its share price and ratcheted up investor pressure, leading Pfizer's board to oust CEO Jeffrey Kindler in December. Successor Ian Read, a longtime Pfizer executive, has since been tweaking Pfizer's research portfolio
-
Pfizer to Buy Pain Drug Developer Icagen for $56M
recent years. That's depressed its share price and ratcheted up investor pressure, leading Pfizer's board to oust CEO Jeffrey Kindler in December. Successor Ian Read, a longtime Pfizer executive, has since been tweaking Pfizer's research portfolio
-
Pfizer lowers amount of executive severance payout
bonus. That still amounts to at least a few million dollars for some officers and nearly $10 million for Chief Executive Jeffrey Kindler . Terminated executives also would be eligible to continue medical and life insurance benefits at employee rates for up
-
Reported talks to buy Wyeth could transform Pfizer
areas and eliminated all new research on heart disease, the world's top killer. That's left Pfizer Chief Executive Jeff Kindler under pressure to take some kind of preemptive action, with investors upset that its share price is barely one-third of
-
Congress Probes Celebrity Drug Ad Endorsements
on consultations with their doctors, not on paid advertisements during a commercial break." In a letter to Pfizer CEO Jeffrey B . Kindler , the congressmen asked for records related to the Lipitor advertising campaign, contractual arrangements with Jarvik
News
-
Health Highlights: Jan. 8, 2008
someone who isn't qualified to give such advice, Dingell said in the statement. He and Stupak sent a letter to Pfizer CEO Jeffrey B . Kindler requesting that the drug company provide the House subcommittee with records relating to Jarvik's relationship with Pfizer
-
Health Highlights: Oct. 18, 2007
physicians. We have therefore concluded that further investment in this product is unwarranted," Pfizer Chief Executive Jeff Kindler said in a prepared statement. There were a number of problems with Exubera, Forbes reported. The drug seemed to decrease
